Autoimmune Diseases  >>  mocravimod (KRP-203)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mocravimod (KRP-203) / Priothera
NCT01294774 / 2010-019689-10: Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

Completed
2
10
Europe
KRP203 - 1.2mg, Placebo to KRP203 - 1.2 mg
Novartis Pharmaceuticals
Subacute Cutaneous Lupus Erythematosus
10/12
10/12

Download Options